CA3059543A1 - Salt of an aminopyrimidine derivative compound, a crystalline form thereof, and a process for preparing the same - Google Patents
Salt of an aminopyrimidine derivative compound, a crystalline form thereof, and a process for preparing the same Download PDFInfo
- Publication number
- CA3059543A1 CA3059543A1 CA3059543A CA3059543A CA3059543A1 CA 3059543 A1 CA3059543 A1 CA 3059543A1 CA 3059543 A CA3059543 A CA 3059543A CA 3059543 A CA3059543 A CA 3059543A CA 3059543 A1 CA3059543 A1 CA 3059543A1
- Authority
- CA
- Canada
- Prior art keywords
- mesylate salt
- crystalline form
- formula
- organic solvent
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/02—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
- C07C303/22—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof from sulfonic acids, by reactions not involving the formation of sulfo or halosulfonyl groups; from sulfonic halides by reactions not involving the formation of halosulfonyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2017-0051687 | 2017-04-21 | ||
| KR20170051687 | 2017-04-21 | ||
| PCT/KR2018/004473 WO2018194356A1 (en) | 2017-04-21 | 2018-04-18 | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3059543A1 true CA3059543A1 (en) | 2018-10-25 |
Family
ID=63857137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3059543A Pending CA3059543A1 (en) | 2017-04-21 | 2018-04-18 | Salt of an aminopyrimidine derivative compound, a crystalline form thereof, and a process for preparing the same |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11453656B2 (enExample) |
| EP (1) | EP3612529A4 (enExample) |
| JP (2) | JP7126514B2 (enExample) |
| KR (3) | KR102629654B1 (enExample) |
| CN (1) | CN110869367B (enExample) |
| AR (1) | AR111469A1 (enExample) |
| AU (2) | AU2018256227B2 (enExample) |
| BR (1) | BR112019021868A2 (enExample) |
| CA (1) | CA3059543A1 (enExample) |
| CO (1) | CO2019011578A2 (enExample) |
| EA (1) | EA201992501A1 (enExample) |
| IL (2) | IL270018B (enExample) |
| MA (1) | MA49696A (enExample) |
| MX (2) | MX392634B (enExample) |
| MY (1) | MY201919A (enExample) |
| NZ (1) | NZ758443A (enExample) |
| PH (1) | PH12019502370A1 (enExample) |
| SA (1) | SA519410342B1 (enExample) |
| SG (1) | SG11201909615YA (enExample) |
| TW (1) | TWI776882B (enExample) |
| UA (1) | UA124364C2 (enExample) |
| WO (1) | WO2018194356A1 (enExample) |
| ZA (1) | ZA201907687B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR111469A1 (es) | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| MY198379A (en) | 2017-07-28 | 2023-08-28 | Yuhan Corp | Improved Process for Preparing Aminopyrimidine Derivatives |
| KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| KR101973074B1 (ko) * | 2018-11-30 | 2019-04-26 | 주식회사 티움바이오 | 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물 |
| US12312329B2 (en) * | 2018-12-21 | 2025-05-27 | Shenzhen Targetrx, Inc. | Aminopyrimidine compound used for inhibiting activity of protein kinase |
| US11459391B2 (en) | 2019-02-26 | 2022-10-04 | Janssen Biotech, Inc. | Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies |
| MX2021013955A (es) * | 2019-05-14 | 2022-03-11 | Janssen Biotech Inc | Terapias de combinación con anticuerpos anti-egfr/c-met biespecíficos e inhibidores de tirosina quinasa de egfr de 3.a generación. |
| JOP20210304A1 (ar) | 2019-05-14 | 2023-01-30 | Janssen Biotech Inc | علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث |
| US11850248B2 (en) * | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| JOP20220184A1 (ar) | 2020-02-12 | 2023-01-30 | Janssen Biotech Inc | علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14 |
| TW202207940A (zh) * | 2020-04-14 | 2022-03-01 | 美商健生生物科技公司 | 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物 |
| WO2022253261A1 (zh) | 2021-06-01 | 2022-12-08 | 杭州领业医药科技有限公司 | Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途 |
| CA3228195A1 (en) | 2023-05-23 | 2025-06-30 | Janssen Biotech Inc | Methods for treatment of non-small cell lung cancer (nsclc) |
| WO2025052273A1 (en) | 2023-09-05 | 2025-03-13 | Janssen Biotech, Inc. | Methods of treating non-small cell lung cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1698623T3 (pl) | 2003-12-25 | 2015-08-31 | Eisai R&D Man Co Ltd | Postać krystaliczna soli 4-(3-chloro-4-(cyklopropyloaminokarbonylo)aminofenoksy)-7-metoksy-6-chinolinokarboksamidu lub jej solwatu i sposoby ich wytwarzania |
| ES2565078T3 (es) | 2004-02-11 | 2016-03-31 | Natco Pharma Limited | Forma polimorfa novedosa de mesilato de imatinib y un proceso para su preparación |
| EP2361248B1 (en) * | 2008-06-27 | 2018-09-19 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| CZ2009570A3 (cs) | 2009-08-26 | 2011-03-09 | Zentiva, K. S. | Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem |
| WO2011060295A1 (en) | 2009-11-13 | 2011-05-19 | Genosco | Kinase inhibitors |
| US9006448B2 (en) * | 2010-12-06 | 2015-04-14 | Msn Laboratories Private Limited | Process for the preparation of benzimidazole derivatives and its salts |
| PT3009431T (pt) * | 2011-07-27 | 2017-12-26 | Astrazeneca Ab | Compostos de 2-(2,4,5-anilino-substituídos)pirimidina como moduladores úteis do egfr para o tratamento do cancro |
| WO2015003571A1 (zh) | 2013-07-08 | 2015-01-15 | 杭州普晒医药科技有限公司 | 达拉菲尼甲磺酸盐的新晶型及其制备方法 |
| JP6468611B2 (ja) | 2014-05-13 | 2019-02-13 | アリアド ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
| TWI730331B (zh) | 2014-10-13 | 2021-06-11 | 南韓商柳韓洋行股份有限公司 | 用於調節ｅｇｆｒ突變型激酶活性的化合物及組成物 |
| CN104788427B (zh) * | 2015-02-05 | 2017-05-31 | 上海泓博智源医药股份有限公司 | 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用 |
| KR101794186B1 (ko) | 2015-10-30 | 2017-11-08 | 한국기술교육대학교 산학협력단 | 전기자동차용 급전장치 |
| AR111469A1 (es) | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| KR20200043618A (ko) | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
-
2018
- 2018-04-13 AR ARP180100945A patent/AR111469A1/es unknown
- 2018-04-18 AU AU2018256227A patent/AU2018256227B2/en active Active
- 2018-04-18 KR KR1020180044850A patent/KR102629654B1/ko active Active
- 2018-04-18 EA EA201992501A patent/EA201992501A1/ru unknown
- 2018-04-18 IL IL270018A patent/IL270018B/en unknown
- 2018-04-18 NZ NZ758443A patent/NZ758443A/en unknown
- 2018-04-18 CN CN201880026342.7A patent/CN110869367B/zh active Active
- 2018-04-18 JP JP2019556610A patent/JP7126514B2/ja active Active
- 2018-04-18 BR BR112019021868-8A patent/BR112019021868A2/pt active Search and Examination
- 2018-04-18 SG SG11201909615Y patent/SG11201909615YA/en unknown
- 2018-04-18 MA MA049696A patent/MA49696A/fr unknown
- 2018-04-18 UA UAA201911263A patent/UA124364C2/uk unknown
- 2018-04-18 TW TW107113234A patent/TWI776882B/zh active
- 2018-04-18 IL IL294666A patent/IL294666B2/en unknown
- 2018-04-18 US US16/605,944 patent/US11453656B2/en active Active
- 2018-04-18 WO PCT/KR2018/004473 patent/WO2018194356A1/en not_active Ceased
- 2018-04-18 CA CA3059543A patent/CA3059543A1/en active Pending
- 2018-04-18 EP EP18787260.1A patent/EP3612529A4/en active Pending
- 2018-04-18 MX MX2019012574A patent/MX392634B/es unknown
- 2018-04-18 MY MYPI2019006145A patent/MY201919A/en unknown
-
2019
- 2019-10-18 PH PH12019502370A patent/PH12019502370A1/en unknown
- 2019-10-18 CO CONC2019/0011578A patent/CO2019011578A2/es unknown
- 2019-10-20 SA SA519410342A patent/SA519410342B1/ar unknown
- 2019-10-21 MX MX2022006357A patent/MX2022006357A/es unknown
- 2019-11-20 ZA ZA2019/07687A patent/ZA201907687B/en unknown
-
2022
- 2022-03-17 US US17/697,655 patent/US11981659B2/en active Active
- 2022-05-23 AU AU2022203486A patent/AU2022203486B2/en active Active
- 2022-08-16 JP JP2022129468A patent/JP7390444B2/ja active Active
-
2023
- 2023-12-18 KR KR1020230184208A patent/KR102835717B1/ko active Active
-
2024
- 2024-03-27 US US18/618,379 patent/US12428401B2/en active Active
-
2025
- 2025-07-11 KR KR1020250093917A patent/KR20250111074A/ko active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12428401B2 (en) | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | |
| KR102011770B1 (ko) | 치환된 피리도피리미딘 화합물 및 flt3 억제제로서의 이의 용도 | |
| AU2024216519B2 (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt | |
| HUE034807T2 (en) | New quinoline-substituted compound | |
| US9388165B2 (en) | Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase | |
| US10906901B2 (en) | Crystal form and salt form of N-phenyl-2-aminopyrimidine compound, and preparation method therefor | |
| KR101929725B1 (ko) | 의학적 적용을 위한 3-(1,2,4-트리아졸로[4,3-a]피리딘-3-일에티닐)-4-메틸-N-(4-((4-메틸피페라진-1-일)메틸)-3-트리플루오로메틸페닐)벤즈아미드의 신규 결정질 염 형태 | |
| TW202128666A (zh) | 氨基嘧啶類化合物甲磺酸鹽的晶型a及其製備方法和應用 | |
| EA041089B1 (ru) | Соль соединения производного аминопиридина, ее кристаллическая форма и способ получения | |
| HK40025158A (en) | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | |
| HK40025158B (zh) | 氨基吡啶衍生物化合物的盐、其结晶形式、以及用於制备它们的方法 | |
| KR20180122493A (ko) | 신규한 tyro 3 저해 화합물, 이의 제조방법, 및 이를 유효성분으로 함유하는 tyro 3 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| EA046959B1 (ru) | Фармацевтическая композиция для перорального введения, содержащая производное аминопиримидина или его соль | |
| EA040294B1 (ru) | Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht6-рецептора |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230414 |
|
| EEER | Examination request |
Effective date: 20230414 |
|
| EEER | Examination request |
Effective date: 20230414 |
|
| EEER | Examination request |
Effective date: 20230414 |